CD38 and chronic myelogenous leukemia, BCR-ABL1 positive: Accordingly, we selected a type I PRMTs inhibitor MS023 to test whether pharmacological inhibition of PRMT1 suppresses the function of LSCs.[29] CML CD34+CD38− cells were treated with MS023 ± imatinib for 48 h, and the apoptotic cells were measured by flow cytometry.